Intrathecal Morphine for Cesarean Delivery

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a randomized double blinded non-inferiority study comparing the duration of pain relief when patients receive one of three doses of spinal morphine. Enrolled patients will be randomly assigned to receive either 50 mcg, 150 mcg, or 250 mcg. All patients will receive standardized postoperative care, including multimodal analgesia. The primary outcome will be the time until the patient requests additional opioid pain medications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Treatments: Morphine

Criteria

Inclusion Criteria:

• Healthy women (ASA 2)

• Between 18 and 45 years old

• Singleton term pregnancies

• Planned neuraxial anesthesia

Exclusion Criteria:

• Refusal to participate

• Known allergy or contraindication to any medication used in the study

• Significant medical or obstetrical disease (ASA ≥ 3)

• Opioid use disorder

• Chronic pain syndrome

• Daily or near daily opioid use within last 3 weeks.

• Patient receiving a Monoamine oxidase inhibitors (MOAi)